Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Oral Doses of LY2881835 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2011
At a glance
- Drugs LY 2881835 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker
- 10 Jun 2017 Biomarkers information updated
- 26 Aug 2011 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 09 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.